Navigation Links
Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
Date:9/24/2010

SAN DIEGO, Sept. 24 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd. Proceeds from the financing will be used to expand the human clinical trials program for CX-4945, including the Phase I trial in patients with multiple myeloma and a series of randomized Phase II trials.

The multi-center Phase I study with CX-4945 will be conducted in patients with relapsed or refractory multiple myeloma. The primary objectives of the study are to determine the safety, tolerance and pharmacokinetic (PK) properties of CX-4945 in multiple myeloma patients and to select the appropriate dose for Phase II trials. Secondary objectives are to investigate the pharmacodynamic (PD) activity of CX-4945 using mechanism and tumor-related PD biomarkers that have been validated in both preclinical and clinical studies. In preclinical studies with multiple myeloma cell lines, CX-4945 inhibited critical CK2-mediated events including key signaling pathways and mediators (PI3K/Akt, NFkB, IL-6) that are known to drive the proliferation of multiple myeloma. These findings, coupled with the need for new agents that target molecular pathways shared by all subtypes of multiple myeloma, highlight CX-4945 as a promising therapeutic agent for multiple myeloma.

A separate Phase I clinical trial in patients with solid tumors evaluating CX-4945 as an orally administered single agent has already established favorable pharmacokinetic and safety profiles. Measurement of mechanism and tumor-related biomarkers in patients established that CX-4945 hits the CK2 targ
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
(Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
(Date:9/15/2014)... The chemistry, taste, and health effects of tea ... published by the nonprofit American Botanical Council (ABC). Recent research ... its effects on the phytochemical compounds in tea ( Camellia ... Dr. Ahmed in the Yunnan province ... for the future of medicinal botanicals. Dr. Ahmed,s report ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... 7 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the ... receipt of preliminary proxies, the Company believes that it has ... ("Merger") by and among Dragon, Chief Respect Limited, Datong Investment ... Yanlin Han . The Merger must be approved by holders ...
... , , ... a 25 percent replacement for petroleum oil more than doubles rubber,s stretchability and reduces its environmental ... Ford,s ... automotive parts such as deflector shields and baffles, radiator deflector shields, cupholder inserts and floor mats ...
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... industry, today announced that it privately placed 357,857 common shares ... with certain members of its Board of Directors and management ... are restricted securities and are subject to the restrictions on ...
Cached Biology Technology:Dragon Pharma announces receipt of preliminary proxies to approve merger 2Dragon Pharma announces receipt of preliminary proxies to approve merger 3Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 2Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 3Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 4DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:9/15/2014)... Earth for the first 500 million years after it ... day, complete with oceans, continents and active crustal plates. ... called the Hadean, has gained substantial new support from ... more than 4 billion years ago with those formed ... possible geological analog for early Earth. , The study ...
(Date:9/15/2014)... cognitive function may play roles in one,s musical aptitude, ... timbre, tone durations, and formal structure in music. , ... that extremes in musical aptitude (extreme capacity/no capacity) are ... having moderate aptitude. , "This is a typical feature ... and it is influenced to varying degrees by environmental ...
(Date:9/15/2014)... from GEOMAR Helmholtz Centre for Ocean Research Kiel ... demonstrated for the first time, that the single ... Emiliania huxleyi , can adapt simultaneously to ... study, the researchers found no evidence for the ... aspects of climate change would interfere with each ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Small algae with great potential 2Small algae with great potential 3
... 2013) As public health authorities across the globe grapple ... of Medicine microbiologists and colleagues have identified the unique resistance ... resistant to carbapenems. Carbapenems are a class of antibiotics ... bacteria, including E. coli and Klebsiella pneumonia ...
... of poultry could be improved by a discovery about how ... chicken,s genetic make-up can affect the signals sent from its ... has had enough to eat. Poultry farmers often have ... to feelings of fullness and can overeat, affecting their ability ...
... , March 26, 2013 Today, Hyland ... Intelligence Corporation (CIC; OTCQB: CICI), a leading ... help organizations automate processes, such as electronic mortgage ... enterprise content management (ECM) solution, OnBase, with ...
Cached Biology News:New study identifies unique mechanisms of antibiotic resistance 2Appetite genes are key to better diets for poultry, study shows 2Hyland Software Partners with Communication Intelligence Corporation (CIC), a Leading Supplier of Electronic Signature Solutions 2Hyland Software Partners with Communication Intelligence Corporation (CIC), a Leading Supplier of Electronic Signature Solutions 3